Top

Published in:

01-09-2019 | Obesity | Review Article

Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment

Authors: Luisa Costa, Roberta Ramonda, Augusta Ortolan, Marta Favero, Rosario Foti, Elisa Visalli, Marco Rossato, Fabio Cacciapaglia, Giovanni Lapadula, Raffaele Scarpa

Published in: Clinical Rheumatology | Issue 9/2019

Abstract

Patients with psoriatic arthritis (PsA) have an increased prevalence of obesity, but mechanisms underlying this association remain unknown and it is unclear if obesity is the cause or effect of PsA. For PsA patients, comorbid obesity may influence their clinical response to systemic treatment, and especially targeted immunomodulators such as anti-tumor necrosis factor (TNF)α. Weight gain has also been associated with anti-TNFα treatment. Consequently, modification of the therapeutic approach may be needed for patients with an inadequate response to TNFα inhibitors. In recent years, interleukin (IL)-12/IL-23 inhibitors have entered clinical practice as a new class of drug for the treatment of PsA, with some data suggesting a lower effect of body weight on their effectiveness. Recent findings demonstrate effective and sustained responses in patients with PsA to ustekinumab, an IL-12/IL-23 inhibitor. This narrative review critically discusses the link between PsA, obesity, and response to therapy. The current role of ustekinumab in this setting is also discussed.

Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am 41:545–568. https://doi.org/10.1016/j.rdc.2015.07.001 CrossRef

Caso F, Del Puente A, Oliviero F, Peluso R, Girolimetto N, Bottiglieri P et al (2018) Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol 37:579–586. https://doi.org/10.1007/s10067-017-3975-0 CrossRefPubMed

World Health Organization (2018) Obesity and overweight. http://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 23 July 2018

Finkelstein EA, Khavjou OA, Thompson H, Trogdon JG, Pan L, Sherry B, Dietz W (2012) Obesity and severe obesity forecasts through 2030. Am J Prev Med 42:563–570. https://doi.org/10.1016/j.amepre.2011.10.026 CrossRefPubMed

Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, Starcevic V, Trajkovic V, Micic D (2009) Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes 33:151–156. https://doi.org/10.1038/ijo.2008.216 CrossRef

Husni ME (2015) Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am 41:677–698. https://doi.org/10.1016/j.rdc.2015.07.008 CrossRef

Al-Mutairi N, Nour T (2014) The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther 14:749–756. https://doi.org/10.1517/14712598.2014.900541 CrossRefPubMed

Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A et al (2011) Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. Dermatol Ther 24:446–451. https://doi.org/10.1111/j.1529-8019.2011.01439.x CrossRefPubMed

Galindez E, Carmona L (2016) Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug. Reumatol Clin 12:307–312. https://doi.org/10.1016/j.reuma.2015.12.005 CrossRefPubMed

10.

Iannone F, Lopalco G, Rigante D, Orlando I, Cantarini L, Lapadula G (2016) Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmun Rev 15:447–450. https://doi.org/10.1016/j.autrev.2016.01.010 CrossRefPubMed

11.

Johnsson HJ, McInnes IB (2015) Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis. Clin Exp Rheumatol 33:S115–S118PubMed

12.

Wang EA, Suzuki E, Maverakis E, Adamopoulos IE (2017) Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol 4:272–277. https://doi.org/10.5152/eurjrheum.2017.17037 CrossRefPubMedPubMedCentral

13.

Iannone F, Santo L, Bucci R, Semeraro A, Carlino G, Paoletti F, Quarta L, Leucci P, Zuccaro C, Marsico A, Scioscia C, D’Onofrio F, Mazzotta D, Muratore M, Cantatore FP, Lapadula G (2018) Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). Clin Rheumatol 37:667–675. https://doi.org/10.1007/s10067-018-3989-2 CrossRefPubMed

14.

Chehimi M, Robert M, Bechwaty ME, Vial G, Rieusset J, Vidal H, Pirola L, Eljaafari A (2016) Adipocytes, like their progenitors, contribute to inflammation of adipose tissues through promotion of Th-17 cells and activation of monocytes, in obese subjects. Adipocyte 5:275–282. https://doi.org/10.1080/21623945.2015.1134402 CrossRefPubMedPubMedCentral

15.

Kanneganti TD, Dixit VD (2012) Immunological complications of obesity. Nat Immunol 13:707–712. https://doi.org/10.1038/ni.2343 CrossRefPubMed

16.

Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4–12PubMed

17.

Aprahamian TR, Sam F (2011) Adiponectin in cardiovascular inflammation and obesity. Int J Inflam 2011:376909. https://doi.org/10.4061/2011/376909 CrossRefPubMedPubMedCentral

18.

Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355CrossRefPubMed

19.

Adya R, Tan BK, Randeva HS (2015) Differential effects of leptin and adiponectin in endothelial angiogenesis. J Diabetes Res 2015:648239. https://doi.org/10.1155/2015/648239 CrossRefPubMedPubMedCentral

20.

Vettor R, Milan G, Rossato M, Federspil G (2005) Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 22(Suppl 2):3–10. https://doi.org/10.1111/j.1365-2036.2005.02587.x CrossRefPubMed

21.

Dikbas O, Tosun M, Bes C, Tonuk SB, Aksehirli OY, Soy M (2016) Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. Int J Rheum Dis 19:672–677. https://doi.org/10.1111/1756-185X.12444 CrossRefPubMed

22.

Toussirot E, Aubin F, Dumoulin G (2014) Relationships between adipose tissue and psoriasis, with or without arthritis. Front Immunol 5:368. https://doi.org/10.3389/fimmu.2014.00368 CrossRefPubMedPubMedCentral

23.

Daien CI, Sellam J (2015) Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response. RMD Open 1:e000012. https://doi.org/10.1136/rmdopen-2014-000012 CrossRefPubMedPubMedCentral

24.

Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD (2011) Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 63:1729–1735. https://doi.org/10.1002/acr.20627 CrossRef

25.

Eder L, Abji F, Rosen CF, Chandran V, Gladman DD (2017) The association between obesity and clinical features of psoriatic arthritis: a case-control study. J Rheumatol 44:437–443. https://doi.org/10.3899/jrheum.160532 CrossRefPubMed

26.

Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG (2010) Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 146:721–726. https://doi.org/10.1001/archdermatol.2010.141 CrossRefPubMed

27.

Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N et al (2014) Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:600–607. https://doi.org/10.1002/acr.22185 CrossRef

28.

Bhole VM, Choi HK, Burns LC, Vera Kellet C, Lacaille DV, Gladman DD, Dutz JP (2012) Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 51:552–556. https://doi.org/10.1093/rheumatology/ker349 CrossRef

29.

Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, Choi HK (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71:1273–1277. https://doi.org/10.1136/annrheumdis-2012-201299 CrossRefPubMedPubMedCentral

30.

Li W, Han J, Qureshi AA (2012) Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 71:1267–1272. https://doi.org/10.1136/annrheumdis-2011-201273 CrossRefPubMedPubMedCentral

31.

McGonagle D, Tan AL, Benjamin M (2008) The biomechanical link between skin and joint disease in psoriasis and psoriatic arthritis: what every dermatologist needs to know. Ann Rheum Dis 67:1–4. https://doi.org/10.1136/ard.2007.080952 CrossRefPubMed

32.

Voiculescu VM, Solomon I, Popa A, Draghici CC, Dobre M, Giurcaneanu C, Papagheorghe LML, Lupu M (2018) Gene polymorphisms of TNF-238G/A, TNF-308G/A, IL10-1082G/A, TNFAIP3, and MC4R and comorbidity occurrence in a Romanian population with psoriasis. J Med Life 11:69–74PubMedPubMedCentral

33.

Mantravadi S, Ogdie A, Kraft WK (2017) Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol 10:899–910. https://doi.org/10.1080/17512433.2017.1329009 CrossRefPubMedPubMedCentral

34.

Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P et al (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33:833–839. https://doi.org/10.1007/s10067-013-2369-1 CrossRefPubMed

35.

Shan J, Zhang J (2018) Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine 86:173–183. https://doi.org/10.1016/j.jbspin.2018.03.007 CrossRefPubMed

36.

Singh S, Facciorusso A, Singh AG, Casteele NV, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ (2018) Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One 13:e0195123. https://doi.org/10.1371/journal.pone.0195123 CrossRefPubMedPubMedCentral

37.

Hojgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L (2016) The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford) 55:2191–2199. https://doi.org/10.1093/rheumatology/kew326 CrossRef

38.

Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, di Minno G (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 65:141–147. https://doi.org/10.1002/acr.21711 CrossRef

39.

Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R, Ca RSG (2014) Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers. Ann Rheum Dis 73:1157–1162. https://doi.org/10.1136/annrheumdis-2012-202812 CrossRefPubMed

40.

Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD (2015) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 74:813–817. https://doi.org/10.1136/annrheumdis-2013-204448 CrossRefPubMed

41.

Puig L (2011) Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 25:1007–1011. https://doi.org/10.1111/j.1468-3083.2011.04065.x CrossRefPubMed

42.

Toussirot E, Mourot L, Dehecq B, Wendling D, Grandclement E, Dumoulin G, On behalf of CBT-506 (2014) TNFalpha blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. Eur J Nutr 53:951–961. https://doi.org/10.1007/s00394-013-0599-2 CrossRefPubMed

43.

Gisondi P, Cotena C, Tessari G, Girolomoni G (2008) Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 22:341–344. https://doi.org/10.1111/j.1468-3083.2007.02429.x CrossRefPubMed

44.

Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A, Chimenti S (2008) Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 57:290–295. https://doi.org/10.1016/j.phrs.2008.02.006 CrossRefPubMed

45.

Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G (2013) Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 168:1124–1127. https://doi.org/10.1111/bjd.12235 CrossRefPubMed

46.

Pirowska M, Obtulowicz A, Lipko-Godlewska S, Gozdzialska A, Podolec K, Wojas-Pelc A (2018) The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor alpha in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. Postepy Dermatol Alergol 35:360–366. https://doi.org/10.5114/ada.2018.77665 CrossRefPubMedPubMedCentral

47.

Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957–970. https://doi.org/10.1056/NEJMra1505557 CrossRefPubMed

48.

Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C (2018) Role of the IL-23/IL-17 Axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci 19:E530. https://doi.org/10.3390/ijms19020530 CrossRefPubMed

49.

Fabbrini E, Cella M, McCartney SA, Fuchs A, Abumrad NA, Pietka TA et al (2013) Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology 145:366–374. https://doi.org/10.1053/j.gastro.2013.04.010 CrossRefPubMedPubMedCentral

50.

Chehimi M, Vidal H, Eljaafari A (2017) Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J Clin Med 6:E68. https://doi.org/10.3390/jcm6070068 CrossRefPubMed

51.

European Medicines Agency Summary of Product Characteristics: Stelara 130 mg (Ustekinumab). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf. Accessed 24 July 2018

52.

Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, Mendelsohn AM, Song M, Zhu Y, Rahman P, McInnes IB, on behalf of the PSUMMIT 1 Study Group (2015) Maintenance of clinical efficacy and radiographic benefit through two years of Ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken) 67:1739–1749. https://doi.org/10.1002/acr.22645 CrossRef

53.

Wendler J, Schwarze I, Schwenke H, Behrens J, Gruppe T, Behrens F (2017) AB0763 Ustekinumab for the treatment of psoriatic arthritis – results of the first interim analysis of the non-interventional study SUSTAIN. Ann Rheum Dis 76:1322. https://doi.org/10.1136/annrheumdis-2017-eular.3764 CrossRef

54.

Wendler J, Movshovich E, Behrens J, Hamann F, Wagener P, Behrens F (2018) Early and long-term treatment response as well as high tolerability lead to high treatment satisfaction of a therapy with ustekinumab in patients with active psoriatic arthritis – results of the non-interventional study SUSTAIN. Ann Rheum Dis 77:A358. https://doi.org/10.1136/annrheumdis-2018-eular.6364 CrossRef

55.

Chimenti MS, Ortolan A, Lorenzin M, Triggianese P, Talamonti M, Costa L, Caso F, Favero M, Teoli M, Galluzzo M, Scarpa R, Punzi L, Perricone R, Ramonda R (2018) Effectiveness and safety of ustekinumab in naive or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clin Rheumatol 37:397–405. https://doi.org/10.1007/s10067-017-3953-6 CrossRefPubMed

56.

Queiro R, Brandy A, Rosado MC, Lorenzo A, Coto P, Carriles C, Alperi M, Ballina J (2018) Minimal disease activity and patient-acceptable symptom state in psoriatic arthritis: a real-world evidence study with ustekinumab. J Clin Rheumatol 24:381–384. https://doi.org/10.1097/RHU.0000000000000751 CrossRefPubMed

Title: Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment
Authors: Luisa Costa
Roberta Ramonda
Augusta Ortolan
Marta Favero
Rosario Foti
Elisa Visalli
Marco Rossato
Fabio Cacciapaglia
Giovanni Lapadula
Raffaele Scarpa
Publication date: 01-09-2019
Publisher: Springer London
Keywords: Obesity
Obesity
Ustekinumab
Vulgar Psoriasis
Psoriatic Arthritis
IL-23 Inhibitor
Published in: Clinical Rheumatology / Issue 9/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04663-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2019

The superb microvascular imaging is more sensitive than conventional power Doppler imaging in detection of active synovitis in patients with rheumatoid arthritis

Evaluation of factors affecting the levels of physical activity in patients with rheumatoid arthritis: a cross-sectional study

Humoral immunity to varicella zoster virus is altered in patients with rheumatoid arthritis

Correction to: Behçet’s disease in Egypt: a multicenter nationwide study on 1526 adult patients and review of the literature

Nailfold capillaroscopy in rheumatology: ready for the daily use but with care in terminology

Pan-American League of Associations for Rheumatology (PANLAR) capillaroscopy study group consensus for the format and content of the report in capillaroscopy in rheumatology

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page